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1. Introduction 
The discovery of penicillin, the Magic bullet in 1928 and its clinical use in 1941 led the 
people to think that mankind has won the war against microbes. With a short span of 
seventy years, antimicrobial discovery from Penicillin to Tigecycline, mankind is facing the 
problem with some hospital strains resistant to almost all antimicrobials, and is busy in 
writing the obituary for antimicrobials. 
Infact, the rising trend of developing resistance to multiple antibiotics in microbes, leading 
to therapeutic failure is a serious problem of global magnitude. P.aeruginosa, Methicillin 
Resistant Staphylococcus aureus (MRSA), Vancomycin resistant Enterococci(VRE), 
Glycopeptide Intermediate Staphylococcus aureus (GISA), Glycopeptide Resistant 
Staphylococcus aureus (GRSA), Acinetobacter baumani, Stenotrophomonas maltophila etc. 
need special attention as they are commonly isolated from Health Care Associated 
Infections(HAI) and belong to Multidrug resistant Organism (MDRO) i.e. they are resistant 
to one or more classes of antibiotics (Harrison & Lederberg, 1998). P. aeruginosa is 
responsible for 10-15% of nosocomial infections worldwide. The β-lactam group of 
antibiotics which include Penicillins, Cephalosporins, Monobactams and Carbapenems are 
mainly used to treat infections caused by Gram negative bacteria. The widespread use of 
antibiotics put tremendous selective pressure on bacteria which develop new mechanisms to 
escape the lethal action of the antibiotics. These infections are difficult to treat because of 
emergence of newer β-lactamases such as Extended Spectum β-lactamases (ESBL), AmpCβ-
lactamases and Carbapenemases. The β-lactamases inactivate β-lactam antibiotics by 
cleaving the structural β-lactam ring. Failure to detect these enzymes producing strains has 
contributed to their uncontrolled spread in Health Care setup and therapeutic failure. 
Major mechanisms causing resistance to the β-lactam antibiotics in P.aeruginosa are the 
production of β-lactamases, reduced outer membrane permeability and altered affinity of 
targetPenicillin binding proteins. (Washington et al, 2006; Pitt, 1990). 
1.1 Classification of β-lactamases 
β-lactamase can be classified according to Functional or Bush Jacoby Mederious classification ( 
Bush et al, 1995), into group 1, 2a, 2be, 2br, 2c, 2d, 2e, 2f and according to molecular or Ambler 
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classification (Ambler, 1980) into Ambler class A,B,C and D. Detection of β-lactamase 
production has been achieved in the past by measuring the production of penicilloic acid, 
which is produced when benzyl penicillin is hydrolysed. The acid production can be detected 
by acidometric method, iodometric method and chromogenic cephalosporin (nitrocephin) 
method (Miles & Amyes, 2008). The first plasmid mediated β-lactamase was described in early 
1960. The TEM1 enzyme was named after the patient Temoniera from whom it was originally 
found in isolated strains of E.coli, (Medeiros, 1984) whereas β-lactamase SHV-1 (Sulphydryl 
variable) is chromosomally encoded in most isolates of Klebsiella pneumoniae but is usually 
plsmid mediated in E.coli (Tz-ouvelekis, 1999). 
1.1.1 Extended spectrum β-lactamases (ESBL) 
ESBLs were first reported in 1983 in Klebsiella pneumoniae from Germany. Typically ESBLs 
are mutant plasmid mediated β-lactamases derived from older broad-spectrum β-
lactamases. The mutations alter the amino acid configuration around active site of β-
lactamases (Thomson, 2001). The first ESBL to be described in 1983 was actually TEM3 ( 
Soughakoff et al, 1980) and now over 130 additional TEMs have been isolated. ESBLs have 
an extended substrate profile that cause hydrolysis of cephalosporins, penicillins and 
aztreonam and are inhibited by β-lactamase inhibitors, such as clavulanate, tazobactam and 
sulbactam. ESBLs are commonly produced by Klebsiella species and Escherichia coli; but 
also occur in other Gram negative bacteria, including Enterobacter, Salmonella, Proteus, 
Serratia marcescens, Pseudomonas aeruginosa, Burkholderia, Acinetobacter species, etc. 
1.1.2 AmpC β-lactamases 
Molecular class C or AmpC primarily hydrolyses cephems (cephalosporins and 
cephamycins) but also hydrolyze penicillins and aztreonam. These enzymes are resistant to 
the currently available β-lactamase inhibitors such as clavulanate, tazobactam and 
sulbactam ( Philippon et al, 2002). With rare exceptions, the hydrolysis of cephamycins, such 
as cefotetan and cefoxitin, is a property that can help to distinguish AmpCs from ESBLs. 
Genes encoding inducible chromosomal AmpC β-lactamases are part of the genomes of 
many Gram negative bacteria specially P.aeruginosa. High level production of AmpC may 
cause resistance to the first, second and third-generation cephalosporins and cephamycins, 
penicillins and β-lactamase inhibitor combination. Higher level AmpC production may 
occur as a consequence of mutation or when the organism is exposed to an inducing agent. 
Cephamycins (e.g. cefoxitin and cefotetan ), ampicillin, and carbapenem are good inducer ( 
Moland et al, 2008). AmpC β-lactamases producing organisms are on rise and leads to 
therapeutic failure if 3rd Generation cephalosporins are given empirically or not tested in the 
laboratory for AmpC β-lactamases production ( Basak et al, 2009). The chromosomally 
mediated AmpC β-lactamases are only inducible. 
1.1.3 Carbapenemases 
These include β-lactamases which cause carbapenem hydrolysis, with elevated carbapenem 
MICs and they belonged to molecular classes A, B and D. Molecular classes A, C and D 
include the β-lactamases with serine at their active site, whereas class B β-lactamases are all 
metalloenzymes with an active site zinc ( Queenan & Bush, 2007). 
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Metallobetalactamases – They belong to molecular class B β-lactamases, and have 3 
characteristics –  
1. Hydrolyze carbapenems 
2. Resistant to clinically used β-lactamase inhibitors and 
3. Inhibited by EDTA, a metal ion chelator. 
Other MBL inhibitors used are 2-mercaptoethanol, sodium mercapto acetic acid (SMA), 2-
mercaptopropionic acid, copper chloride and ferric chloride (Arkawa et al, 2000). MBLs have a 
broad substrate spectrum and in addition to carbapenems, they can hydrolyze cephalosporin 
and penicillins but cannot hydrolyse aztreonam. Interestingly, not all of the MBLs readily 
hydrolyze nitrocefin. The first MBL detected were chromosomally encoded and was detected 
in Bacillus cereus ( Lim et al, 1988). Since then there has been a dramatic increase in detection 
and spread of acquired or transferable families of these MBLs. There are 5 major families of 
acquired MBLs (IMP, VIM, SPM, GIM and SIM) ( Toleman et al, 2007). In 1990, IMP-1, the 1st 
MBL encoded on plasmid, was discovered in Japan ( Watanabe et al, 1991). The MBLs are 
located on integrons and are incorporated as gene cassettes.When these integrons become 
associated with plasmids or transposons, transfer between bacteria is facilitated.  
Classification of MBLS 
MBLS are classified into 3 subclasses—B1,B2 and B3. Subclass B1 and B3 are divided by 
aminoacid homology, bind 2 zinc atoms for optimal hydrolysis and have broad hydrolysis 
spectrum. Subclass B2 are inhibited when a second zinc atom is bound and preferentially 
hydrolyse carbapenem ( Free et al, 2005).  
Molecular class A carbapenemase – Class A serine carbapenemases belong to functional 
group 2f include chromosomally encoded NMC( not metalloenzyme carbapenemase), IMI 
(Imipenem hydrolyzing β-lactamase) and SME(Serratia marscenscens enzyme) and plasmid 
mediated KPC (Klebsiella pneumoniae carbapenemase) and GES/IBC(integron borne 
cephalosporinase) ( Queenan & Bush, 2007). All have the ability to hydrolyse carbapenems, 
cephalosporins, penicillins and aztreonem and all are inhibited by clavulanate and 
tazobactam. The chromosomal class A carbapenemase are infrequently found and can be 
induced by imipenem and cefoxitin. The KPC ( Klebsiella pneumoniae carbapenemase) 
producing strains are found in Klebsiella pneumoniae, Enterobacter species, Salmonella 
species and other Enterobacteriaceae ( Hossain et al, 2004; Miriagou et al, 2003). 
Class D Serine carbapenemases: The OXA (Oxacillin hydrolysing) β-lactamase with 
carbapenemase activity was detected by Patow et al in 1993 and the enzyme was purified 
from Acinetobacter baumani (Queenan & Bush, 2007). They have been also found in 
Enterobacteriaceae and P.aeruginosa and were described as penicillinase capable of 
hydrolyzing oxacillin and cloxacillin ( Bush & Sykes, 1987; Naas & Nordmann, 1999). They 
were poorly inhibited by clavulanic acid and EDTA and were designated as ARI-1 
(Acinetobacter Resistant to Imipenem) and reside on large plasmid. The OXA 
carbopenemases have hydrolytic activity against penicillins, some cephalosporins and 
imipenem. The widespread use of reserved antibiotics such as β-lactam /β-lactamases 
inhibitor combinations, monobactams and carbapenem has caused persistent exposure of 
bacterial strains to a multitude of β-lactam leading to overproduction of β-lactamases 
(Goossens et al, 2004; Manoharan et al, 2010; Lee et al, 2003). Consequently the emergence of 
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carbapenem resistance is a world-wide public health concern since carbabapenems are used 
as last resort to treat serious infections caused by ESBL producing organisms. 
Approximately 40% strains of P.aeruginosa are resistant to anti-pseudomonal drugs 
including carbapenems. Therefore, early detection of of ESBL, AmpC β-lactamase & MBL 
producing P. aeruginosa strains is of crucial importance for prevention of their inter and 
intra hospital dissemination.  
1.2 Aims and objectives 
The present study was undertaken with the aim to study Pseudomonas aeruginosa with 
special reference to β-lactamase production isolated in the Department of Microbiology, 
Jawaharlal Nehru Medical College, Wardha ( M. S.), India. 
1.2.1 To fulfill the aim the following objectives were taken 
 To study the prevalence of Extended Spectrum β-lactamases (ESBL), Amp C β-
lactamases, Metallobetalactamases (MBL) producing Pseudomonas aeruginosa strains, 
isolated from different clinical samples of patients attending the Hospital 
 To study the antibiotic susceptibility profile of Extended Spectrum β-lactamases (ESBL), 
Amp C β-lactamases and Metallobetalactamases (MBL) producing Pseudomonas 
aeruginosa strains isolated. 
2. Material and methods 
The study was conducted from 1st September 2008 to August 2010 (2 year period). A total 
number of 250 P.aeruginosa strains were isolated from different clinical samples e.g. urine, 
pus and wound swab, blood, catheter tips, endotracheal tube secretions, different body 
fluids etc. received from indoor as well as outdoor patients departments (IPD &OPD) of our 
hospital, which is a tertiary care hospital in a rural set-up. P.aeruginosa strains were 
characterized according to conventional identification tests. P.aeruginosa ATCC 27853 were 
used as positive control for all conventional tests. All antibiotic disks and culture media 
used in the study were procured from HiMedia laboratories Pvt. Limited, India. Ethylene 
Diamine Tetraacetic acid (EDTA) and 3-amino phenylboronic acid (APB) were procured 
from Sigma-Alderich. 
2.1 Antibiotic susceptibility testing 
All 250 P.aeruginosa strains were subjected to antibiotic susceptibility testing to different 
antimicrobial agents using Mueller-Hinton agar plates by Kirby-Bauer disk diffusion method 
according to CLSI guidelines (CLSI Document M2-A9, 2006). Using sterile swab, lawn culture 
of the test strain (turbidity adjusted to 0.5 McFarland standard) was made on Mueller Hinton 
Agar plate. With all aseptic precaution, the antibiotic disks were put on that inoculated plate. 
Six antibiotic disks were put on a 90mm diameter plate. The antibiotic sensitivity tests were 
put for aminoglycosides such as amikacin (Ak-30µg), netilimicin (Nt-30µg); cephalosporin 
such as ceftazidime(Ca-30µg), cefepime(Cpm-30µg); fluoroquinolones i.e. ciprofloxacin(Cf- 
5µg); monobactams i.e. aztreonam (Ao-30 µg); carbapenems such as imipenem(I-10µg), 
meropenem(Mr-10µg); piperacillin/tazobactam (Pt-100/10µg ), ceftazidime/clavulanic acid 
(Cac-30µg /10 µg) and polymyxin B (Pb-300µg) etc. (Fig. 1) 
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Fig. 1. Antibiotic susceptibility test. 
Detection of newer β-lactamases 
Though several methods both phenotypic and genotypic have been described for detection of 
newer β-lactamases, we restricted our study only to phenotypic methods. There is no CLSI 
guideline given for detection of ESBL, AmpC β-lactamases ans MBL producing P.aeruginosa.  
2.1.1 Detection of extended spectrum β-lactamases (ESBL) 
Screening test: ESBL production was detected by reduced susceptibility to Ceftazidime, 
Cefotaxime.  
Confirmatory tests: As per Clinical and Laboratory Standard Institute (CLSI) guidelines 
for Enterobacteriaceae (Waynepa CLSI, 2008; Storenburg, 2003), we used the same 
combined disk method as confirmatory test for Pseudomonas aeruginosa also, as the 
principle remains the same.  
1. Combined Disk Method (Carter et al, 2000)  
Broth cultures of test strains were adjusted to McFarland 0.5 standard and used to 
inoculate Mueller Hinton agar plates with a sterile swab. Commercialized disks 
containing ceftazidime (Ca) 30 µg and ceftazidime plus clavulanate (Cac) 30µg plus 
10µg respectively were used in this method. An increase in diameter of ≥5mm with 
ceftazidime plus clavulanate (Cac) disk as compared to ceftazidime(Ca) disk alone was 
considered positive for ESBL detection. All 250 P. aeruginosa strains were also tested 
using piperacillin (Pc)100 µg & piperacillin-tazobactam (Pt) 100 µg plus 10 µg 
respectively in combination. 
2. E test ESBL strip (Washington et al, 2006) 
The E-test ESBL confirmatory test strips are based on the CLSI dilution method. The 
strip has concentration gradients of ceftazidime (TZ) 0.5 to 32 µg/ml on one half and 
ceftazidime 0.064 to 4 µg/ml plus 4 µg/ml clavulanic acid (TZL) on another half . The 
ESBL E-test was performed and interpreted using test strains and Quality Control 
strains according to the manufacturerer’s instructions. In this method lawn culture of 
test strain was done on a Mueller Hinton agar plate. With a sterile forceps the ESBL E-
test strip was placed onto the inoculated plate. After overnight incubation at 37°C, the 
zone of inhibition was read from two halves of the strip. MIC ratio of 
ceftazidime/ceftazidime clavulanic acid (TZ/TZL) ≥ 8 or deformation of ellipse or 
phantom zone present was considered as positive for ESBL production.  
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2.1.2 Detection of Amp C β-lactamases  
For detection of AmpC class of β-lactamases, no satisfactory technique has been established 
till date as per CLSI guidelines. Induction of C β-lactamase synthesis was Amp based on the 
disc approximation assay using several inducer substrate combinations.  
Screening test: Several inducer/substrate combinations disks like Cefoxitin/Piperacillin, 
Imipenem/Ceftazidime,Imipenem/Cefotaxime, Imipenem/Cefoxitin, Imipenem/Piperacillin 
-Tazobactum were used as described by Dunne and Hardin et al. Imipenem and cefoxitin were 
used as inducers of AmpC β-lactamases (Dunne & Hardin, 2005). 
Interpretation: Strains were considered inducible if a positive test was obtained with any of 
the inducer/substrate combinations. A test was considered positive if the zone of inhibition 
was reduced by ≥2 mm on the induced side of the substrate disc or even blunting of substrate 
zone of inhibition adjacent to inducer disc. Also, if the zone of inhibition produced by 
ceftazidime/ceftazidime-clavulanic acid (Cac) disk was ≥2mm less than the zone produced by 
a ceftazidime (Ca) disk, the strain was considered to be inducible Amp C positive. Similarly, 
same criteria was used for piperacillin & piperacillin/tazobactam (Pc/Pt) disks.  
Confirmatory test: Disk potetiation(DP) test and Double disk synergy test (DDST) using 3-
aminophenylboronic acid (APB) (100mg/ml dissolved in DMSO) (Yagi et al, 2005). An 
increase in zone size of ≥5mm around the Ceftazidime- APB disk compared to ceftazidime 
only disk was recorded as a positive result for disk potentiation test. In DDST, the presence 
of change in the shape of growth inhibitory zone around ceftazidime or cefotaxime disk 
through the interaction with the 3- Aminophenyl boronic acid containing disk was 
interpreted as positive for AmpC production. 
2.1.3 Detection of metallobetalactamases (MBL) 
All imipenem resistant strains were screened for Carbapenemase activity by Classical Hodge 
Test and Modified Hodge Test (MHT) (Lee et al, 2001a; 2003b). Pseudomonas aeruginosa 
strains which were positive by Classsical Hodge Test(IHT) and Modified Hodge Test (MHT) 
were tested for metallobetalactamase (MBL) production by Imipenem/EDTA double disk 
synergy test (Lee et al, 2001)and disk potentiation test or imipenem-EDTA combined disk test 
(Yong et al, 2002) using Di-potassium EDTA (10µl of 0.5 M). 
Imipenem-EDTA double disk synergy test (DDST) ( Lee et al, 2001) 
The IMP-EDTA double disk synergy test was performed for detection of 
metallobetalactamases. Test strains i.e. Pseudomonas aeruginosa (turbidity adjusted to 0.5 
McFarland standard ) were inoculated on to Mueller Hinton agar plate. After drying, a 10μg 
Imipenem disk and a blank sterile filter paper disk (6mm in diameter, Whartman filter paper 
no.2) were placed 10mm apart from edge to edge. 10 μl of 50mM zinc sulfate solution was 
added to the 10 μg imipenem disk. Then, 10μl of 0.5 M EDTA(Sigma, USA) solution was 
applied to the blank filter paper disk. As disodium-EDTA is difficult to be solubilised in sterile 
water, we had used dipotassium-EDTA which is easily soluble in sterile water. Enhancement 
of the zone of inhibition towards the EDTA disk was interpreted as a positive result. 
Disk Potentiation test or Imipenem-EDTA combined disk test (Young et al, 2002) 
The test was performed for detection of metallobetalactamases. Test strains (turbidity 
adjusted to 0.5 McFarland standard ) were inoculated on to Mueller Hinton agar plate. Two 
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imipenem disk (10 µg) were placed on the plate wide apart and 10 μl of 50mM zinc sulphate 
solution was added to each of the imipenem disks. Then 10µl of 0.5 M EDTA solution was 
added to one of the disk to obtain the desired concentration. The inhibition zones of the 
imipenem and imipenem-EDTA disks were compared after 16-18 hours of incubation at 
35°C. If the increase in inhibition zone with the Imipenem and EDTA disk was ≥7 mm than 
the imipenem disk alone, it was considered as MBL positive.  
The MBL producing strains were further confirmed by using MBL – E test strip (AB 
bioMerieux) (Walsh et al, 2002). 
MIC ratio of Imipenem /Imipenem-EDTA (IP/IPI) of ≥8 or deformations of ellipse or 
phantom zone indicate MBL production by MBL E-test.  
2.2 Observations and results 
Maximum 204(81.6%) P.aeruginosa strains were isolated from Indoor Patient Department 
(IPD). No newer β-lactamase producing strains were isolated from patients attending Out 
Patient Department 
 
Fig. 2. Isolation of Pseudomonas aeruginosa strains from OPD, IPD and ICU patients.  
Fig. 3 shows 165 (66%) P.aeruginosa strains were ESBL, AmpC β-lactamases and MBL 
producers. 
 
Fig. 3. Prevalence of newer β-lactamases producing P. aeruginosa strains (n=250). 
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P.aeruginosa 
ESBL AmpC MBL 
No. Percentage No. Percentage No. Percentage 
n=250 100 40 105 42 28 11.2 
Table 1. Prevalence of ESBL, AmpC β-lactamase and MBL producing P. aeruginosa (n=250) 
Amongst the 100 ESBL (Fig. 4) and 105 Amp C β-lactamase producers (Fig. 5 & 6), 68 (27.2%) 
P. aeruginosa strains had produced both ESBL as well as AmpC β-lactamases. 28 (11.2%) P. 
aeruginosa strains were Metallobetalactamase (MBL) producers.  
 
Fig. 4. Detection of ESBL( Combined disk method ) 
Detection of AmpC β-lactamases (Figure 5&6) 
 
Fig. 5. Inducer-substrate combination disk test. 
Fig. 7 shows amongst 100 ESBL and 105 AmpC β-lactamase producers 68 (41.2%) strains had 
produced both ESBL as well as AmpC β-lactamases. There was no strain which produced all 
the 3 types of β-lactamases. Similarly, no strain produced ESBL or AmpC β-lactamase along 
with MBL.  
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Fig. 6. DDST & DP test using 3-Aminophenyl-boronic acid (3-APB). 
 
Fig. 7. Incidence of different newer β-lactamases producing P.aeruginosa strains(n=165) 
Table 2 shows that out of 250 P. aeruginosa strains studied, 31 (12.4 %)were imipenem 
resistant and 28 (11.2 %) were metallobetalactamase (MBL) producers. 31 imipenem 
resistant strains were screened for carbapenem hydrolysis by Classical Hodge test (HT) & 
modified Hodge test (MHT). Amongst these 31 imipenem resistant P. aeruginosa strains, 28 
(90.3%) were positive for Classical Hodge test (HT) & modified Hodge test (MHT) for 
carbapenem hydrolysis and these 28 strains were also positive for metallobetalactamase 
(MBL) production by Double disk synergy test (DDST) and disk potentiation test (DP). 
Imipenem 
resistant P. 
aeruginosa 
Screening test for 
carbapenem hydrolysis 
Confirmatory test for MBL 
Classical 
Hodge test 
Modified 
Hodge test 
Double disk 
synergy test 
Disk 
potentiation 
test 
MBL 
E-test 
n = 31 28 28 28 28 28 
Table 2. Prevalence of MBL producing P. aeruginosa (n =250) 
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These 28 strains were also confirmed for metallobetalactamase (MBL) production by using 
MBL E-test strip (AB bioMerieux). MBL E-test (Fig. 9) shows MIC ratio of imipenem IP/ 
imipenem-EDTA IPI for test strain P. aeruginosa as 16/1 i.e. 16 and MBL E-test positive. The 
phantom zone shown in Fig. 9 is another criteria for MBL E-test positivity. MBL E-tests done 
for those 28 P. aeruginosa strains showed that the MIC ratio of imipenem / imipenem-
EDTA i.e. IP/IPI were > 8 such as 16/1 for 9 strains, 24/1.5 for 3 strains, 32/1 for 5 strains, 
48/1 for 8 strains, 64/1 for 2 strains and 128/1 for 1 strain.  
Confirmation of MBL by E-test : Figure 8 & 9 
 
Fig. 8. Quality control: P.aeruginosa ATCC 27853 (MBL E test negative). 
 
Fig. 9. MBL E-test (positive). 
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Fig. 10 shows from ICU 6 (14.3%) strains produced both ESBL and AmpC β-lactamases 
whereas 9(21.4%) strains produced MBL. 
 
 
Fig. 10. Isolation of different β-lactamases producing P. aeruginosa strains from ICU. 
 
 
 
*others include throat swab, vaginal swab, ear swab, bronchial wash, tip of catheter & drain fluid.  
Fig. 11. Isolation of β-lactamases producing P.aeruginosa strains from different clinical 
specimens. 
In the present study, maximum P.aeruginosa strains isolated from pus and wound swab, 73 
(29.2%) followed by 60(24%) from urine. The fig. 11 shows 26(49%) P.aeruginosa strains 
isolated from sputum sample were both ESBL and AmpC β-lactamase producer. 50% 
P.aeruginosa strains isolated from endotracheal tube secretions were MBL producers. 
Though no MBL producing strains were isolated from blood culture.  
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Fig. 12 shows maximum 36.2% strains isolated from Medicine ward produced both ESBL 
and AmpC β-lactamase. From surgery ward maximum 10(35.7%) strains were MBL 
producers. No MBL producing P.aeruginosa strains were isolated from Neonatal Intensive 
Care Unit(NICU) and 3(20%) strains were only ESBL producers. 
 
 
Fig. 12. Isolation of β-lactamases producing P. aeruginosa strains from different clinical 
specialities  
Fig. 13 shows that P.aeruginosa strains showed a high degree of resistance to cefepime (90.4%), 
cefoxitine(91.6%) and ceftazidime(67.2%). However effective antimicrobial agents were found 
to be polymyxin B (100%), Imipenem(87.6%) and piperacillin-tazobactum (86%) sensitive. 
 
 
Fig. 13. Antibiotic susceptibility profile of P. aeruginosa strains (n=250)  
Fig. 14 shows most effective antimicrobial agent against ESBL andAmpC β-lactamase 
producing P.aeruginosa strains were Imipenem(100%) and Polymyxin-B(100%). However, 
sensitivity of ESBL and AmpC β-lactamase producers to piperacillin-tazobactam were 100% 
and 82.8% respectively. 
www.intechopen.com
 
Pseudomonas Aeruginosa and Newer -Lactamases: An Emerging Resistance Threat 
 
193 
 
Fig. 14. Antibiotic susceptibility profile of ESBL & Amp C β-lactamases producing 
P.aeruginosa strains  
Fig.15 shows all(100%) MBL positive isolates were sensitive to polymyxin-B. 1(3.7%) each 
MBL producing strain was sensitive to Amikacin and Netilmicin respectively. But no MBL 
producing strain was susceptible to Aztreonam. 
 
Fig. 15. Antibiotic susceptibility profile of MBL & non-MBL P. aeruginosa strains  
2.3 Discussion 
Pseudomonas aeruginosa is one of the most important microorganisms which causes 
problems clinically as a result of its high resistance to antimicrobial agents and is therfore a 
particularly dangerous & dreaded bug. Despite the discovery of ESBL, Amp C β-lactamases 
and MBL at least a decade ago, there remains a low level of awareness of their importance 
and many clinical laboratories have problems in detecting ESBL& Amp C β-lactamases. 
Failure to detect these enzymes has contributed to their uncontrolled spread and commonly 
to therapeutic failures. 
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Detection problems arise especially with organisms that produce an inducible Amp C β-
lactamases, as clavulanate can induce high level production of Amp C , which may obscure 
recognition of ESBLs ( Moland et al, 2008). According to Clinical & Laboratory Standards 
(CLSI) interpretive definations, ESBLs do not always increase MICs to levels characterized 
as resistant ( Livermore, 2002). Not only that ESBL producing organisms may give false 
sensitive zones in routine disk diffusion test. The number of infections caused by Amp C β-
lactamases producing P. aeruginosa is on rise and poses a threat to patients due to 
therapeutic failure if they remain undetected ( Arora & Bal, 2005). Metallobetalactamase 
(MBL) producing P.aeruginosa is an emerging threat and a cause of concern for treating 
physicians as it can hydrolyze carbapenems which are given as a last resort to the patient 
having infection with ESBL and AmpC β-lactamase producing P.aeruginosa. The MBLs 
have become more notorious as therapeutically available inhibitors are not available and for 
their potential for rapid and generalized dissemination to different other Gram negative 
bacilli. Hence, accurate identification of MBL producing strains are very urgently needed. 
Though PCR gives specific and accurate results, it’s use is limited to few laboratories 
because of it’s high cost and different types of ESBLs, AmpCβ-lactamases and 
metallobetalactamases (MBLs) present worldwide ( Moland et al, 2008b). 
In the present study 81.6% P.aeruginosa strains were isolated from IPD patients Algun et al 
from Turkey in 2004 reported isolation of P. aeruginosa 61% from IPD patients. Basak et al 
in 2009 reported 89.3% isolation from IPD and 10.7% from ICU from our hospital.  
In the present study, co-existence of MBL producing P. aeruginosa was not observed along 
with ESBL & Amp C producers. Saha et al in 2010 reported 86% strains producing both MBL 
and Amp C β-lactamases while only one strain was observed to produce both ESBL and 
MBL. In the present study 68(27.2%) strains were both ESBL & Amp C β-lactamases 
producers amongst 250 P. aeruginosa strains studied. 
6(22.2%) MBL producing strains were isolated from Medicine ICU. Sarkar et al in 2006 
reported 36.4% of imipenem resistance in nosocomially infected patients with P. aeruginosa. 
In present study, we found 15 (35.7%) P. aeruginosa from NICU and all were from blood 
cultures of neonates and all were imipenem sensitive. Only 3 (20%) of these were found to 
be positive for ESBL production. Arkawa et al, 2000 recommended testing ceftazidime-
resistant isolates for MBL production because in their study some MBL producing Gram 
negative bacilli were inhibited by low concentration of imipenem and they were difficult to 
detect. But Lee et al, 2001 reported that in their study, not a single MBL-producing isolates 
were detected among imipenem susceptible isolates. 
In Japan, Sugino et al, 2001 used only carbapenem non-susceptible isolates for screening of 
MBL. Hence we also used carbapenem resistant isolates for detection of MBL. Though 
Arkawa et al, 2000 and other authors have done DDST & Disc potentiation test with 
ceftazidime and EDTA, in our study we used imipenem and EDTA for DDST & Disc 
potentiation test. As in our study, even in non MBL producing P.aeruginosa strains, the 
ceftazidime resistance was quite high (69.8%). The MBL producing strains may also have 
another ceftazidime resistance mechanism (Lee et al, 2003b). With such type of strains, 
DDSTs using an imipenem disc can show positive results for MBL but a ceftazidime disc can 
not; just as a cefepime disc but not a ceftazidime disc can detect extended spectrum β-
lactamase (ESBL) production in Amp-C β-lactamase producing strains. 
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Though Franklin et al, 2006 have reported that 87% of their MBL producing 
Enteobacteriaceae isolates had >30mm of zone with aztreonam, we did not find any MBL 
producing P.aeruginosa strain to be susceptible to aztreonam. This can only be explained by 
the fact that there are presence of some other mechanisms for aztreonam resistance in P. 
aeruginosa strains isolated. 
Aggarwal et al in 2008 found that polymyxin B was the most effective antibiotic recording 
0% resistance, similar was the finding of our study. In our study we found 67.2% resistance 
against ceftazidime which was quite high and corelated well with the study of Behra et al in 
2008 who had reported 70% resistance to ceftazidime. 
3. Conclusion  
Microbial drug resistance is now a global problem due to newer β-lactamases produced by 
Gram-negative bacteria including Pseudomonas aeruginosa. E-test and Polymerase chain 
reaction (PCR) can be used for accurate detection of newer β-lactamases , but both are costly 
and require expertise and cannot be done routinely.  
Hence to conclude, for detection of ESBL, combined disk method using 
piperacillin/piperacillin-tazobactam (Pc/Pt), for detection of Amp C β-lactamases 
confirmatorty Disk potentiation test using 3-aminophenylboronic acid and for detection of 
MBL producing P. aeruginosa disk potentiation test using imipenem-EDTA should be done 
by all clinical Microbiolgy laboratories to prevent its dissemination and also for a good 
therapeutic outcome as these tests are economical, easy to perform and quite specific. 
4. Acknowledgment 
The author highly acknowledge the Datta Meghe Institute of Medical Sciences, Deemed to 
be University for funding this project. 
5. References 
Aggarwal G., Lodhi R B., Kamalakar U P., Khadase R K., Jalgaokar S V. (2008). Study of 
metallobetalactamases production in clinical isolates of P. aeruginosa. Indian J Med 
Microbiol. Vol 26 No.4 pp. (349-351). 
Algun U., Arisoy A., Gunduz T., Ozbakkaloglu B. (2004). The resistance of Pseudomonas 
aeruginosa strains to Fluoroquinolone group of antibiotics. Indian J Med Microbiol. 
Vol 22 No.2 pp. (112-114). 
Ambler, R. P. (1980). The structure of β-lactamases. Phil. Trans. R.Soc. Lond. B. Biol. Sci. Vol 
289 pp. (321–331). 
Arkawa Y., Shibata N., Shibayama K., Kurokawa H., Yogi T. Fusiwara H, et al. (2000). 
Convenient test for screening metallobetalactamases producing gram-negative 
bacteria using thiol compounds. J Clin Microbiol Vol 38 pp. (40 – 43). 
Arora S., Bal M. (2005). Amp C β-lactamases producing bacterial isolates from Kolkata 
hospital. Indian J Med Res. Vol 122 pp. ( 224-233). 
Basak S., Khodke M., Bose S., Mallick SK. (2009). Inducible AmpC Beta-Lactamase 
Producing Pseudomonas Aeruginosa Isolated In a rural Hospital of Central India. 
Journal of Clinical and Diagnostic Research. Vol 3 pp. (1921-1927). 
www.intechopen.com
 
Infection Control – Updates 
 
196 
Behra B., Mathur P., Das A., Kapil A., Sharma V. (2008). An evaluation of four different 
phenotypic techniques for detection of metallobetalactamases producing 
Pseudomonas aeruginosa. Indian J Med Microbiol Vol 26 No.3 pp. (233-237). 
Bush, K., and R. B. Sykes. (1987). Characterization and epidemiology of β-lactamases. 
Elsevier Science Publishers BV, Philadelphia, PA. 
Bush K., Jacoby GA., Medeiros A. (1995). A functional classification scheme for beta 
lactamase and its correlation with molecular structure. Antimicrob Agents 
Chemother. Vol 39 pp. (1211-1233). 
Carter MW., Oakton KJ., Warner M., Livermore DM. (2000). Detection of extended spectrum 
beta lactamases in Klebsiellae with the Oxoid combination disk method. J Clin 
Microbiol . Vol 38 pp. (4228-4232). 
Clinical and Laboratory Standards Institute. (2006). Performance standards for antimicrobial disk 
tests; Approved Standards, 9th ed. CLSI Document M2- A9, Vol. 26 No 1. Wayne PA. 
Dunne WM. and Hardin DJ. (2005). Use of Several Inducer and substrate Antibiotic 
Combinations in a Disk Approximation Assay format to screen for AmpC 
induction in patient isolates of Pseudomonas aeruginosa, Enterobacter spp, 
Citrobacter spp and Serratia spp. J Clin Microbiol . Vol 15 pp. (5945-5949). 
Franklin C., Liolios L., Peleg AY. (2006). Phenotypic Detection of carbapenem susceptible 
Metallobetalactamase producing Gram-negative bacilli in the clinical laboratory. J 
of Clin Microbiol. Vol 44 No.9 pp. (3139-3144). 
Free J.M., Galleni M., Bush K., Didiberg O. (2005). Is it necessary to change the classification 
of β-lactamases? J. Antimicrob. Chemother. Vol 55 pp. (1051-1053). 
Goossens H., Malhotra Kumar S., Eraksoy H., Unal S., Grabein B., Masterton R. et al. (2004). 
MYSTIC study group: Results of two world wide surveys into physician awareness 
and perceptions of extended spectrum spectrum beta lactamases. Clin Microbiol 
Infect. Vol 10 pp. (760-762). 
Hossain, A., Ferraro MJ., Pino RM., Dew III RB., Moland ES., Lockhart TJ., Thomson KS., 
Goering RV., Hanson ND. (2004). Plasmid mediated carbapenem-hydrolyzing 
enzyme KPC-2 in an Enterobacter sp. Antimicrob. AgentsChemother. Vol 48 pp. 
(4438–4440). 
I.O.M.(1998) eds. Harrison, P.F. & Lederberg J. pp. (8-74), National Academy Press 
Washington, DC. 
Lee K., Chong Y., Shin H B., Kim Y A., Yong D., Yum J H. (2001). Modified Hodge and 
EDTA disk synergy test to screen metallobetalactamases producing strains of 
Pseudomonas spp and Acinetobacter spp. Clin Microbiol Infect. Vol 7 pp. (88 – 91). 
Lee K., Lim Y S., Yong D., Yum J H., Chong Y. (2003). Evaluation of Hodge test and 
imipenem-EDTA double disk synergy test for differentiation of 
metallobetalactamases producing clinical isolates of Pseudomonas spp and 
Acinetobacter spp. J Clin Microbiol. Vol 4 pp. (4623 – 4629). 
Lee K., Lee WG., Uh Y., Ha GY., Cho J., Chong Y. (2003). VIM and IMP – type 
metallobetalactamase producing Pseudomonas spp. and Acinetobacter spp in 
Korean hospitals. Emerg Infect Dis. Vol 9 pp. (868-871). 
Lim HM., Pene J.J., Shaw RW. (1988). Cloning, nucleotide sequence and expression of the 
Bacillus cereus 5/B/6 β-lactamase II structural gene. J. Bacteriol. Vol 170 pp. (2873-
2878). 
www.intechopen.com
 
Pseudomonas Aeruginosa and Newer -Lactamases: An Emerging Resistance Threat 
 
197 
Livermore DM. (2002). Multicentre evaluation of the VITEK 2 Advanced Expert System for 
interpretive reading of antimicrobial resistance tests. J Antimicrob Chemother. Vol 49 
pp. (289-300). 
Manoharan A., Chatterjee S., Mathai D., SARI Study Group. (2010). Detection and 
Characterization of metallobetalactamases producing Pseudomonas aeruginosa. 
Indian J Med Microbiol . Vol 28 No.3 pp. (241-243). 
Me deiros A A. (1984). β-lactamases Br. Med Bull. Vol 40 pp. (18-27). 
Miles RS., Amyes SGB. 2008 Laboratory control of antimicrobial therapy chapter 8 In Mackie 
& McCartney’s Practical Medical Microbiology, 14th ed, JG Collee, AG Fraser, BP 
Marmion, A Simmons, Editors, pp. (151-178) Churchil Livingston, ISBN: 978-81-
312-0393-4, Indian Reprints. 
Miriagou, V., Tzouvelekis L. S., Rossiter S., Tzelepi E., Angulo F.J., Whichard J.M. (2003). 
Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A 
carbapenemase KPC-2. Antimicrob.Agents Chemother. Vol 47 pp. (1297–1300). 
Moland E S., Kim S., Hong S G., Keneeth & Thomson. (2008). Newer β-lactamases: Clinical 
& Laboratory Implication Part 1. Clinical Microbiology Newsletter, Vol 30 No.10 pp. 
(71-78). 
Naas, T., P. Nordmann. (1999). OXA-type β-lactamases. Curr. Pharm.Des. Vol 5 pp. (865–879). 
Philippon A., Arlet G., Jacoby GA. (2002). Plasmid-determined Amp C type β-lactamases. 
Antimicrob Agents Chemother. Vol 46 pp. (1-11). 
Pitt T L. (1990). Pseudomonas: vol 2 chapter 2.12. Topley & Wilson Principles of Bacteriology, 
Virology and Immunity, 8th ed, MT Parker & BI Duerden, Eds., pp. (256-269). Edward 
Arnold, ISBN : 0 340 88565 3., London, UK. 
Queenan AM., Bush K. (2007). Carbapenemases : the versatile β-lactamases. Clinical 
Microbiology Review, Vol 20 No.3 pp. (440-458). 
Saha R., Jain S., Kaur IR. (2010). Metallobetalactamase producing Pseudomonas species – a 
major cause of concern among hospital associated urinary tract infection. J Indian 
Med Assoc. Vol 108 No.6 pp. (344-348). 
Sarkar B., Biswas D., Prasad R. (2006). A clinicomicrobiological study on the importance of 
Pseudomonas in nosocomially infected ICU patients with special reference to 
metallobetalactamases production. Indian J Pathol Microbiol. Vol 49 pp. (44-48). 
Soughakoff W., Goussard S., Courvalin P. (1988) TEM-3-β-lactamases which hydrolyzes 
broad spectrum cephalosporins, is derived from the TEM-2 penicillinases by two 
amino acid substitutions. FEMS Microbiol Lett. Vol.56 pp. (343-348). 
Stόrenburg E., Mack D. (2003). Extended-spectrum beta-lactamases: Implications for the 
clinical microbiology laboratory, therapy, and infection control. J Infect Vol 47 pp. 
(273-295). 
Sugino Y., Iinuma Y., Nada T., Tawada Y., Amano H., Nakamura T., Hasegawa Y., 
Shimokata K., Shibata N., Arkawa Y. (2001). Antimicrobiol activities and 
mechanism of carbapenem resistance in clinical isolates of carbapenem resistant P. 
aeruginosa and Acinetobacter spp. J Jpn. Assoc. Infect. Dis. Vol 75 pp. (662–670). 
Thomson K. S. (2001). Controversies about Extended-Spectrum and AmpC Beta-Lactamases. 
Emerging Infectious Diseases Vol 7 No.2 pp. (333-336). 
Toleman MA., Vinodh H., Sekar U., Kamat V., Walsh TR. (2007). blaVIM-2 harboring 
integrons isolated in India, Russia, and the United States arise from an Ancestral 
www.intechopen.com
 
Infection Control – Updates 
 
198 
Class 1 integron predating the formation of the 3’ conserved sequence. Antimicrob 
Agents & Chemother Vol 51 No.7 pp. (2636-2638). 
Tzouvelekis L S., Bonomo R A. (1999). SHV-type beta-lactamases. Curr. Pharm Des. Vol 5 pp. 
(847-864). 
Walsh, T. R., Bolmstrom A., Qwarnstrom A., GalesA. (2002). Evaluation of a new Etest for 
detecting metall-lactamases in routine clinical testing. J. Clin. Microbiol. Vol 40 pp. 
(2755–2759). 
Washington CW Jr., Stephen DA., Williams MJ., Elmer WK., Gary WP., Paul CS., Gail LW. 
(2006). Antimicrobial Susceptibility Testing chapter 17 In Koneman’s Colour Atlas 
and Textbook of Diagnostic Microbiology, 6th ed, pp. (945-1021) Lippincott Williams & 
Wilkins, ISBN : 10: 0-7817-3014-7., Philadelphia PA, USA. 
Watanabe M., Iyobe S., Inove M., Mitsuhashi S. (1991) Transferable imipenem resistance in 
P. aeruginosa. Antimicrob Agent Chemother . Vol 35 pp. (147-151). 
Wayne PA. (2008). Performance standards for antimicrobial susceptibility testing; 18th 
informational supplement. Clin Lab Standards Inst. M100-S18. 
Yagi T., Wachino J., Kurokawa H., Suzuki S., et al. (2005). Practical methods using boronic 
acid compounds for identification of class C β-lactamase producing Klebsiella 
pneumoniae and Escherichia coli. J of Clin Microbiol. Vol 43 No.6 pp. (2551-2558). 
Yong D., Lee K., Yum J H.., Shin H B., Rossolinism, Chong Y. (2002) Imipenem – EDTA disk 
method for differentiation of metallobetalactamases producing clinical isolates of 
Pseudomonas spp and Acinetobacter spp. J Clin Microbiol . Vol 40 pp. (3798 –3801). 
www.intechopen.com
Infection Control - Updates
Edited by Dr. Christopher Sudhakar
ISBN 978-953-51-0055-3
Hard cover, 198 pages
Publisher InTech
Published online 22, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Health care associated infection is coupled with significant morbidity and mortality. Prevention and control of
infection is indispensable part of health care delivery system. Knowledge of Preventing HAI can help health
care providers to make informed and therapeutic decisions thereby prevent or reduce these infections.
Infection control is continuously evolving science that is constantly being updated and enhanced. The book will
be very useful for all health care professionals to combat with health care associated infections.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Silpi Basak, Ruchita O. Attal and Monali Rajurkar (2012). Pseudomonas Aeruginosa and Newer β-Lactamases:
An Emerging Resistance Threat, Infection Control - Updates, Dr. Christopher Sudhakar (Ed.), ISBN: 978-953-
51-0055-3, InTech, Available from: http://www.intechopen.com/books/infection-control-updates/pseudomonas-
aeruginosa-and-newer-lactamases-an-emerging-resistance-threat
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
